Ai-5452 colocado no sistema – suzana gontijo versão origianal em português preprint juliana tofacitinibe tópico no tratamento da alopecia areata

Baixar 0.88 Mb.
Tamanho0.88 Mb.
1   2   3   4   5   6
Received on:

Oct 17, 2019

Accepted on:

Jan 9, 2020




Figure 1. (A) Before topical tofacitinib; (B) Two months after topical tofacitinib; (C) Four months after discontinuing topical tofacitinib

Alopecia areata is an autoimmune disease and the second most frequent cause of non-scarring hair loss. Several treatments have been described but are associated to low efficacy, particularly in the more resistant clinical forms. Janus kinase inhibitors are a new therapeutic option, and it may become the first line treatment in the next few years, as topical or oral use.(1-4)

A 23-year-old female white female patient, with a history of alopecia areata for 12 years, presented diffuse hair loss in the scalp and part of the eyebrow. She had used oral steroids, cyclosporin and methotrexate, with no response on the right eyebrow (Figure 1A). She initiated on topical tofacitinib 2% (Chemistry Rx Compound and Specialty Pharmacy, Philadelphia, USA), once a day, and follow-up every 4 weeks. Hair growth was observed 4 weeks after initiating treatment (Figure 1B) and, two months later, there was complete hair growth of the eyebrow and of other alopecia sites. Four months after discontinuing the treatment, she maintains a positive response (Figure 1C).

Alopecia areata is a clinical manifestation of autoimmunity, presenting as hair loss, nails changes and association with other conditions, such as diabetes, vitiligo, rheumatoid arthritis and hypothyroidism (Hashimoto´s disease). It affects 2% of population. There are several subtypes of alopecia areata, and the most frequent forms are localized and universalis. It is known that infectious diseases, anxiety crises and hormone disorders may trigger its onset in genetically predisposed individuals, due to collapse of immune privilege of hair follicles. Experience with the topical use has been recently published by a team from Yale University, and our group has published many reports on oral use in the past 4 years.(5-9) We believe the use herein reported is one of the first cases described in 2019.

Compartilhe com seus amigos:
1   2   3   4   5   6

© 2019
enviar mensagem

    Página principal